Freenome agreed to go public via a SPAC merger that will provide roughly $330 million of proceeds and a $240 million PIPE commitment from health-care investors. The company told investors the financing will accelerate commercialization plans for its SimpleScreen colorectal cancer blood test, currently under FDA review, and support expected multi-test launches in 2026. Freenome framed the transaction as critical to scaling regulatory filings, manufacturing and go‑to‑market partnerships ahead of potential FDA clearance. Investors and competitors will watch whether Freenome can translate pivotal and JAMA‑reported clinical data into reimbursement and market share against incumbents such as Guardant Health. The deal also reflects continued appetite among public and private investors for diagnostics plays tied to near-term commercial opportunities.